今日盘中，疫苗制造商诺瓦瓦克斯医药（Novavax）股价大跌5.07%，引发市场关注。这一跌势可能与美国疾病预防控制中心（CDC）即将召开的疫苗指南审查会议有关。
据悉，CDC的免疫实践咨询委员会（ACIP）将于本周召开为期两天的会议，审查多种疫苗的使用指南。会议议程包括讨论呼吸道合胞病毒（RSV）和基孔肯雅病疫苗的指导方针，以及审查2025-2026年COVID-19疫苗接种建议。值得注意的是，专家小组可能会考虑缩小COVID-19疫苗接种人群范围，这可能对包括诺瓦瓦克斯在内的疫苗制造商产生潜在影响。
目前，CDC建议6个月及以上人群接种最新的COVID-19疫苗。如果ACIP决定缩小接种范围，可能会影响疫苗需求，从而对诺瓦瓦克斯等公司的业务前景产生不利影响。投资者似乎正在消化这一潜在风险，导致诺瓦瓦克斯股价出现明显下跌。然而，具体会议结果尚未公布，市场反应可能会随后续消息而变化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.